AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15367512
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg/day
Trial: 15741421
Drug: Diet/lifestyle counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet/lifestyle counseling plus immediate fluvastatin 80 mg/day
Trial: 15741421
Drug: Diet/lifestyle counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet/lifestyle counseling only, with initiation of fluvastatin 80 mg/day following occurrence of future nonfatal MACE
Trial: 10232418
Drug: SK+early OP
RxNorm normalized name: OP-145
DrugBank: OP-145 (DB05672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK+early OP (early surgical drainage with adjunctive intrapleural fibrinolysis)
Trial: 10232418
Drug: IP-SK (adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP-SK (adjunctive intrapleural streptokinase)
Trial: 8914031
Drug: ACE inhibitor,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor, lisinopril (N = 18)
Trial: 8914031
Drug: Nondihydropyridine calcium
RxNorm normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondihydropyridine calcium channel blockers (NDCCBs), verapamil SR (N = 8) or diltiazem SR (N = 10)
Trial: 8914031
Drug: Beta blocker,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blocker, atenolol (N = 16)
Trial: 6195026
Drug: Dermovate ointment
RxNorm normalized name: clobetasol Topical Ointment [Temovate]
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dermovate ointment
Trial: 6195026
Drug: Betnovate ointment
RxNorm normalized name: Betnovate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betnovate ointment (betamethasone valerate 0.1%)
Trial: 6195026
Drug: Propaderm Forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propaderm Forte cream (beclomethasone dipropionate 0.5%)
Trial: 6195026
Drug: Propaderm ointment
RxNorm normalized name: beclomethasone dipropionate Topical Ointment [Propaderm A]
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propaderm ointment (beclomethasone dipropionate 0.025%)
Trial: 6195026
Drug: Nerisone Forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerisone Forte ointment (diflucortolone valerate 0.3%)
Trial: 6195026
Drug: Nerisone ointment
RxNorm normalized name: Nerisone
DrugBank: Difluocortolone (DB09095)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerisone ointment (diflucortolone valerate 0.1%)
Trial: 6195026
Drug: Adcortyl ointment
RxNorm normalized name: triamcinolone acetonide Topical Ointment [Adcortyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adcortyl ointment (triamcinolone acetonide 0.1%)
Trial: 6195026
Drug: Ledercort ointment
RxNorm normalized name: triamcinolone acetonide Topical Ointment [Ledercort]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledercort ointment (triamcinolone acetonide 0.1%)
Trial: 6195026
Drug: Extemporaneous dilutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extemporaneous dilutions of Adcortyl and Ledercort ointments (triamcinolone acetonide 0.025%)
Trial: 27599328
Drug: Bevacizumab nasal
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab nasal spray 25 mg
Trial: 27599328
Drug: Bevacizumab nasal
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab nasal spray 50 mg
Trial: 27599328
Drug: Bevacizumab nasal
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab nasal spray 75 mg
Trial: 15890740
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg intranasal buserelin followed by 100 microg every 3 days (group B)
Trial: 15890740
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg intranasal buserelin followed by 100 microg every 2 days (group C)
Trial: 15890740
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg intranasal buserelin followed by 100 microg every day (group D)
Trial: 17392540
Drug: Glimepiride (1-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1-8 mg once daily)
Trial: 3381638
Drug: Iodinated salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodinated salt (20 mg of iodine as iodate/kg salt consumed, assumed consumption of 5 g salt per day)
Trial: 21605278
Drug: Iodopovidone (20mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodopovidone (20mL of a 10% solution)
Trial: 16570572
Drug: Somatostatin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (250 microg bolus plus infusion at 250 microg/hour for 48 hours)
Trial: 7914470
Drug: 135 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg/m2 administered as a single dose over 1 hour
Trial: 7914470
Drug: 135 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg/m2 administered in divided daily doses for 3 days, each over 1 hour
Trial: 27506677
Drug: Constraint-Induced Aphasia
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-Induced Aphasia Therapy (CIAT) for 3 hours per day (10 workdays, total 30 hours)
Trial: 27506677
Drug: Conventional communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional communication treatment with same intensity without constraints
Trial: 27506677
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy twice a day plus group therapy (total 14 hours)
Trial: 25976708
Drug: Fast-setting polyvinyl
RxNorm normalized name: Polyvinyl Alcohol
DrugBank: Polyvinyl alcohol (DB11060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fast-setting polyvinyl siloxane (PVS) impression material with heavy body/light body (HB/LB) combination (Imprint 4; 3M ESPE)
Trial: 25976708
Drug: Conventional PVS
RxNorm normalized name: PV
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional PVS impression material with HB/LB combination (Imprint 3; 3M ESPE)
Trial: 14731059
Drug: Zotepine (Nipolept)
RxNorm normalized name: zotepine
DrugBank: Zotepine (DB09225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotepine (Nipolept) [12.5-150 mg/day]
Trial: 11736772
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion (0-300 microg x kg(‐1) x min(‐1))
Trial: 11736772
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no esmolol infusion)
Trial: 31255988
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy (n=5)
Trial: 26817175
Drug: Tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen citrate 20 mg/day
Trial: 26817175
Drug: Tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen citrate plus Folate 5 mg/day
Trial: 26817175
Drug: Folate 5
RxNorm normalized name: folate 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folate 5 mg/day
Trial: 24843716
Drug: Empagliflozin 5
RxNorm normalized name: empagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 5 mg
Trial: 27929674
Drug: Empagliflozin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (all doses)
Trial: 18975504
Drug: Intramuscular placentrex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular placentrex injection along with two-week conventional therapy
Trial: 12846709
Drug: Dolasetron 0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron 0.35 mg.kg‐1
Trial: 11772810
Drug: Dolasetron 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron 12.5 mg
Trial: 11151878
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg i.v. azathioprine over 36 h
Trial: 11151878
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg i.v. azathioprine over 36 h
Trial: 11151878
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg i.v. azathioprine as three 8‐h infusions over 3 days
Trial: 9120123
Drug: Standard CVVHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CVVHD blood lines and heparin concentration (100 units/ml)
Trial: 9120123
Drug: Modified circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified circuit design with heparin delivered in a more dilute volume (10 units/ml)
Trial: 9120123
Drug: Pre-heparin APTT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-heparin APTT
Trial: 6326927
Drug: No sodium
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No sodium bicarbonate supplement
Trial: 24310049
Drug: Prescription opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription opioid analgesics (oral)
Trial: 22701017
Drug: TPTD 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPTD 20 μg once daily by sc injection
Trial: 22701017
Drug: ZOL 5
RxNorm normalized name: danazol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZOL 5 mg by iv infusion
Trial: 17959576
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care services (usual care plus standardized services from a clinical pharmacist, including an initial comprehensive in-home medication assessment and two follow-up visits)
Trial: 15463834
Drug: Tobramycin nebuliser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin nebuliser solution (TNS) 300 mg by aerosol twice daily (b.i.d.)
Trial: 9828870
Drug: Homeopathy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathy treatment for warts
Trial: 9828870
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for warts
Trial: 8466742
Drug: Nitrendipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10 mg once daily)
Trial: 1790542
Drug: Nitrendipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10 mg twice daily)
Trial: 19543129
Drug: Bazedoxifene 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 40 mg
Trial: 17106318
Drug: Extended-release metoprolol
RxNorm normalized name: metoprolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release metoprolol tartrate
Trial: 10878702
Drug: Postprandial changes
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial changes in glucose, insulin, triglyceride, and non‐esterified fatty acids (NEFA) after consuming a test meal containing 45% fat.
Trial: 8933487
Drug: 5.5% CHO-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.5% CHO-electrolyte solution (E)
Trial: 8933487
Drug: 6.9% CHO-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.9% CHO-electrolyte solution (L)
Trial: 21114603
Drug: Dapagliflozin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 50 mg with pioglitazone 45 mg
Trial: 21114603
Drug: Dapagliflozin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 20 mg with metformin 1000 mg
Trial: 21114603
Drug: Dapagliflozin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 20 mg with glimepiride 4 mg
Trial: 21114603
Drug: Dapagliflozin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 20 mg with sitagliptin 100 mg
Trial: 17096386
Drug: CCAP intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCAP intervention (combined cognitive‐behavioral therapy and pharmacotherapy)
Trial: 9820380
Drug: PyloriTek test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PyloriTek test in cases without eradication therapy
Trial: 9820380
Drug: PyloriTek test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PyloriTek test in cases with eradication therapy
Trial: 9820380
Drug: PyloriTek test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PyloriTek test used more than 4 months after eradication therapy
Trial: 35211
Drug: Amylobarbitone sodium
RxNorm normalized name: Amylobarbitone sodium
DrugBank: Amobarbital (DB01351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amylobarbitone sodium 100 mg
Trial: 31583252
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU of vitamin D3 daily for 30 consecutive months
Trial: 31583252
Drug: CYP27B1 (rs10877012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP27B1 (rs10877012) G/T genotype
Trial: 16446322
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m2 intravenously on day 1
Trial: 16446322
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m2 intravenously on day 1 with raltitrexed 3 mg/m2
Trial: 6410104
Drug: Fast neutron
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast neutron therapy (average energy, 6 MeV)
Trial: 6410104
Drug: Linac x-ray
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linac x-ray therapy (10 MV)
Trial: 6410104
Drug: Linac x-ray
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linac x-ray therapy
Trial: 6410104
Drug: Fast neutron
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast neutron therapy and Linac x-ray therapy
Trial: 26204126
Drug: COC pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COC pills
Trial: 22453191
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg intranasal midazolam
Trial: 22453191
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg intranasal midazolam
Trial: 22453191
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intravenous midazolam
Trial: 19236375
Drug: Intranasal desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal desmopressin (IN‐DDAVP)
Trial: 17577015
Drug: Boost dose
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boost dose of 16 Gy (2,661 patients)
Trial: 17577015
Drug: No boost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No boost dose (2,657 patients)
Trial: 31394283
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus albumin (study group)
Trial: 21952668
Drug: MDMA 50
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA 50 mg
Trial: 16830130
Drug: MDMA 100
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA 100 mg
Trial: 10671903
Drug: MDMA 150
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA 150 mg
Trial: 10671903
Drug: MDMA (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (all doses tested)
Trial: 9348549
Drug: m-chlorophenylpiperazine (mCPP)
RxNorm normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-chlorophenylpiperazine (mCPP) 0.1 mg/kg during TRP depletion
Trial: 9348549
Drug: m-chlorophenylpiperazine (mCPP)
RxNorm normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-chlorophenylpiperazine (mCPP) 0.1 mg/kg during sham depletion
Trial: 26024940
Drug: Combined Oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Oral Contraceptives (COC)
Trial: 29352713
Drug: Sipuleucel-T immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sipuleucel-T immunotherapy
Trial: 22648716
Drug: Glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solution with alcohol (21 g alcohol, 25 g carbohydrates)
Trial: 22648716
Drug: Beer (4.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beer (4.5% alcohol by volume, 25 g carbohydrates)
Trial: 22648716
Drug: Nonalcoholic beer
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonalcoholic beer (25 g carbohydrates)
Trial: 22648716
Drug: Reference glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference glucose solution (25 g carbohydrates)
Trial: 15972322
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C supplementation (250 mg three times per week for 2 months)
Trial: 2538962
Drug: Simultaneous radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous radiation and chemotherapy (group 1)
Trial: 2538962
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy followed by radiation (group 2)
Trial: 2538962
Drug: Chemotherapy responders
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy responders in group 2
Trial: 25008011
Drug: Salacia reticulata
RxNorm normalized name: Salacia reticulata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salacia reticulata and Vitamin D₃ (200 mg of Salacia reticulata and 1.6 µg Vitamin D₃ 3 times/day with meals)
Trial: 16873329
Drug: Custom-designed dental
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Custom-designed dental scaling instruments with a large diameter (10 mm) and light weight (15 g)
Trial: 16873329
Drug: Custom-designed dental
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Custom-designed dental scaling instruments lighter than 15 g
Trial: 12615252
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium 15 mmol twice daily (Magnosolv‐Granulat, total magnesium 365 mg provided as magnesium citrate)
Trial: 11234440
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of steam and aerosol using municipal drinking water (group C)
Trial: 8868018
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone regimen
Trial: 1519685
Drug: Topical nonsteroidal
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nonsteroidal anti-inflammatory gel
Trial: 30194849
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (GTN) patch
Trial: 30194849
Drug: No GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No GTN patch
Trial: 30194849
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment continued
Trial: 30194849
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment stopped
Trial: 21080972
Drug: QUIT-PRIMO intervention
RxNorm normalized name: Primor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QUIT-PRIMO intervention (e-referral with paper information-prescription referral)
Trial: 21080972
Drug: Augmented patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented patient smoking cessation website (with access to a tobacco treatment specialist online, motivational emails, and an online support group)
Trial: 12834860
Drug: Brivudin 1
RxNorm normalized name: Brivudine
DrugBank: Brivudine (DB03312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivudin 1 x 125 mg for 7 days
Trial: 12834860
Drug: Acyclovir 5
RxNorm normalized name: acyclovir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 5 x 800 mg for 7 days
Trial: 10230711
Drug: Tyrosine-rich drink
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tyrosine-rich drink (2 g tyrosine, 5 daily doses)
Trial: 1871541
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg twice daily)
Trial: 3914014
Drug: Merck‐Sharp and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merck‐Sharp and Dohme pneumococcal vaccine (14 serotypes)
Trial: 27433096
Drug: Topical hemocoagulase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hemocoagulase spray
Trial: 27433096
Drug: Traditional 8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional 8% norepinephrine spray